Torrent Pharma Eyes 10–12% Growth, Plans Divisional Expansion

⚗️

expects 10–12% annual growth, aiming to outpace the market by 2–3 percentage points. In its latest update, the company announced plans for 5–10 annual launches from previously filed products, despite valuation impact from approval delays. Expansion of divisions and HQs is underway to support launches. In the US, Torrent anticipates new competition over the next 12 months, while in Brazil, 63 molecules await ANVISA approval.